News & Updates

Show Multimedia Only

Ultraprocessed foods are the new cigarettes: study

17 Feb 2026 by

Ultraprocessed foods (UPFs) are associated with several preventable diseases and must be viewed not only through a nutritional lens but also as addictive, industrially engineered substances, which can be likened to cigarettes, suggests a recent study.

Ultraprocessed foods are the new cigarettes: study

17 Feb 2026

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

11 Feb 2026 by

Patients with potentially resectable hepatocellular carcinoma (HCC) may receive neoadjuvant nivolumab plus ipilimumab therapy, followed by surgery, to improve their survival, suggests a study.

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

11 Feb 2026

Beyond the bedside: the pharma physician

09 Feb 2026

The role of physicians in the pharmaceutical industry has grown markedly over the past decade. No longer confined to clinical settings, doctors now contribute to an expanding range of functions that shape the development, evaluation, and responsible use of medicines. Their clinical grounding, patient‑centered judgment, and ethical orientation make them uniquely positioned to guide drug development, medical affairs, drug safety, regulatory compliance, health economics, and even corporate leadership. As pharmaceutical medicine matures into a recognized scientific discipline and medical specialty, physicians strengthen the industry’s ability to uphold accuracy, transparency, and patient‑focused decision‑making, an evolution aligned with global expectations for robust regulatory authority, real‑world evidence, and scientifically grounded engagement with healthcare systems. (Setia et al., 2018).

Beyond the bedside: the pharma physician

09 Feb 2026

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

08 Feb 2026

Treatment with the combination of savolitinib plus osimertinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutation and MET amplification, as shown in the phase III SACHI trial.

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

08 Feb 2026

GLP-1RA bests aspirin for CRC prevention

06 Feb 2026 by

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) appears to confer greater protection against the development of colorectal cancer (CRC) as compared with aspirin, according to a retrospective study.

GLP-1RA bests aspirin for CRC prevention

06 Feb 2026

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

06 Feb 2026 by

Treatment with zanidatamab combined with tislelizumab and/or chemotherapy (CT) significantly improves progression-free survival (PFS) in patients with HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA), as shown in the primary analysis from HERIZON-GEA-01.

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

06 Feb 2026

$Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma$

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

06 Feb 2026

In the treatment of patients with relapsed or refractory follicular lymphoma, adding tafasitamab to lenalidomide and rituximab appears to improve progression-free survival (PFS) while having an acceptable safety profile, according to the phase III inMIND study.

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

06 Feb 2026

Adjuvant S-1 + oxaliplatin yields survival benefit in G/GEJ cancer

06 Feb 2026 by

Combining S-1 and oxaliplatin (SOX) as an adjuvant chemotherapy significantly improves overall survival (OS) and disease-free survival (DFS) compared with S-1 alone in patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, according to the final results of the CAPITAL trial presented at ASCO GI 2026.

Adjuvant S-1 + oxaliplatin yields survival benefit in G/GEJ cancer

06 Feb 2026

Palbociclib plus letrozole on par with paclitaxel for early breast cancer

05 Feb 2026

Dual anti-HER2 blockade with a chemotherapy-free backbone of palbociclib plus letrozole may serve as an alternative treatment to patients with HR-positive/HER2-positive early breast cancer, suggests the phase II TOUCH study, noting similar rates of pathological complete response (pCR) to that of paclitaxel.

Palbociclib plus letrozole on par with paclitaxel for early breast cancer

05 Feb 2026

Abemaciclib extends survival in early breast cancer

05 Feb 2026 by

The combination of adjuvant abemaciclib and endocrine therapy (ET) significantly improves overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer compared with ET alone, the phase III monarchE trial has shown.

Abemaciclib extends survival in early breast cancer

05 Feb 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

Ultraprocessed foods are the new cigarettes: study

Ultraprocessed foods are the new cigarettes: study

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Beyond the bedside: the pharma physician

Beyond the bedside: the pharma physician

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

GLP-1RA bests aspirin for CRC prevention

GLP-1RA bests aspirin for CRC prevention

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

Adjuvant S-1 + oxaliplatin yields survival benefit in G/GEJ cancer

Adjuvant S-1 + oxaliplatin yields survival benefit in G/GEJ cancer

Palbociclib plus letrozole on par with paclitaxel for early breast cancer

Palbociclib plus letrozole on par with paclitaxel for early breast cancer

Abemaciclib extends survival in early breast cancer

Abemaciclib extends survival in early breast cancer